Your browser doesn't support javascript.
loading
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
Capeding, Maria Rosario; Sil, Arijit; Tadesse, Birkneh Tilahun; Saluja, Tarun; Teshome, Samuel; Alberto, Edison; Kim, Deok Ryun; Park, Eun Lyeong; Park, Ju Yeon; Yang, Jae Seung; Chinaworapong, Suchada; Park, Jiwook; Jo, Sue-Kyoung; Chon, Yun; Yang, Seon-Young; Ryu, Ji Hwa; Cheong, Inho; Shim, Kyu-Young; Lee, Yoonyeong; Kim, Hun; Lynch, Julia A; Kim, Jerome H; Excler, Jean-Louis; Wartel, T Anh; Sahastrabuddhe, Sushant.
Afiliação
  • Capeding MR; Research Institute for Tropical Medicine, Manila, The Philippines.
  • Sil A; International Vaccine Institute, Seoul, Republic of Korea.
  • Tadesse BT; International Vaccine Institute, Seoul, Republic of Korea.
  • Saluja T; International Vaccine Institute, Seoul, Republic of Korea.
  • Teshome S; CORE Group Polio Project, Ethiopia.
  • Alberto E; Research Institute for Tropical Medicine, Manila, The Philippines.
  • Kim DR; International Vaccine Institute, Seoul, Republic of Korea.
  • Park EL; International Vaccine Institute, Seoul, Republic of Korea.
  • Park JY; International Vaccine Institute, Seoul, Republic of Korea.
  • Yang JS; International Vaccine Institute, Seoul, Republic of Korea.
  • Chinaworapong S; International Vaccine Institute, Seoul, Republic of Korea.
  • Park J; International Vaccine Institute, Seoul, Republic of Korea.
  • Jo SK; International Vaccine Institute, Seoul, Republic of Korea.
  • Chon Y; International Vaccine Institute, Seoul, Republic of Korea.
  • Yang SY; SK bioscience, Seoul, Republic of Korea.
  • Ryu JH; SK bioscience, Seoul, Republic of Korea.
  • Cheong I; SK bioscience, Seoul, Republic of Korea.
  • Shim KY; SK bioscience, Seoul, Republic of Korea.
  • Lee Y; SK bioscience, Seoul, Republic of Korea.
  • Kim H; SK bioscience, Seoul, Republic of Korea.
  • Lynch JA; International Vaccine Institute, Seoul, Republic of Korea.
  • Kim JH; International Vaccine Institute, Seoul, Republic of Korea.
  • Excler JL; International Vaccine Institute, Seoul, Republic of Korea.
  • Wartel TA; International Vaccine Institute, Seoul, Republic of Korea.
  • Sahastrabuddhe S; International Vaccine Institute, Seoul, Republic of Korea.
EClinicalMedicine ; 27: 100540, 2020 Oct.
Article em En | MEDLINE | ID: mdl-33150320
ABSTRACT

BACKGROUND:

Typhoid causes significant mortality among young children in resource-limited settings. Conjugate typhoid vaccines could significantly reduce typhoid-related child deaths, but only one WHO-prequalified typhoid conjugate vaccine exists for young children. To address this gap, we investigated the safety, immunogenicity and dose-scheduling of Vi-DT typhoid conjugate vaccine among children aged 6-23 months.

METHODS:

In this single center, observer blind, phase II trial, participants were randomly assigned (221) to receive one or two doses of Vi-DT or comparator vaccine. Anti-Vi IgG titer and geometric mean titers (GMT) were determined at 0, 4, 24 and 28 weeks. Data were analyzed using per-protocol and immunogenicity (a subset of intention-to-treat analysis) sets. The trial is registered with ClinicalTrials.gov (NCT03527355).

FINDINGS:

Between April and July 2018, 285 children were randomized; 114 received one or two doses of Vi-DT while 57 received comparator. 277 completed the study follow-up per protocol; 112 and 110 from single- and two-dose Vi-DT schedules, respectively and 55 from the placebo group were included in the per protocol analysis. Safety profile is satisfactory. Thirteen serious adverse events were reported during the 28-week follow-up, none of which were related to Vi-DT. The seroconversion rate four weeks after the first dose was 100% (95% CI 98·3-100) in Vi-DT recipients and 7·0% (95% CI 2·8-16·7) in comparator recipients (p<0·0001). Similarly, the seroconversion rate 4 weeks after the second dose was 98·2% (95% CI 93· 6-99·5) and 21·8% (95% CI 13·0-34·4) among Vi-DT and comparator groups, respectively (p<0·0001). Anti-Vi IgG GMT was significantly higher in Vi-DT than in control group at all post-vaccination visits (p<0·0001).

INTERPRETATION:

Both single and two doses of Vi-DT vaccine are safe, well tolerated, and immunogenic for infants and toddlers in a moderately endemic setting.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: EClinicalMedicine Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Revista: EClinicalMedicine Ano de publicação: 2020 Tipo de documento: Article